Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase

Leukemia Research
Chad CheringtonRuben A Mesa

Abstract

The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN) who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor. Although allogeneic stem cell transplantation (allo-SCT) is considered potentially curative, very few patients have been reported who have undergone allo-SCT for MPN-BP; therefore the success rate remains unknown. In a retrospective review, we identified 13 patients with an MPN transformation to blast phase after a median 9 years (range 5 months to 30 years); 8 (median age 55) continued to allo-SCT within 6 months. Induction chemotherapy cleared blood/marrow blasts in 60% (6/10) (2 declined therapy, 1 had early death). At the time of allo-SCT, 5/8 patients were in complete remission (CR) of their leukemia or had returned to MPN chronic phase (CP), 2 had residual blood blasts and 1 was refractory with >5% marrow blasts. At follow-up (median 20.3 months), 6 patients are alive in CR of both their leukemia/MPN. All 5 patients in CR/CP at pre-allo-SCT remain alive in remission, while 2/3 with persistent blood/marrow blasts relapsed and expired. We conclude that MPN-BP can be cured by allo-SCT in a significant percentage of patients, but that adequate leukemic...Continue Reading

References

Sep 9, 2004·Bone Marrow Transplantation·M DitschkowskiA H Elmaagacli
Nov 16, 2004·The American Journal of Medicine·Francesco PassamontiMario Lazzarino
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Feb 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniella M B KerbauyH Joachim Deeg
Aug 23, 2007·Blood·Giovanni BarosiUNKNOWN Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis
Jan 13, 2009·European Journal of Haematology·Khadija AbdulkarimBjörn Andréasson
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
Dec 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O CiureaUday Popat

❮ Previous
Next ❯

Citations

Oct 2, 2012·Molecular Diagnosis & Therapy·Raoul TibesRuben A Mesa
Aug 24, 2013·Expert Opinion on Emerging Drugs·Raoul Tibes, Ruben A Mesa
Dec 15, 2015·Current Hematologic Malignancy Reports·Auro ViswabandyaVikas Gupta
Feb 11, 2015·Bone Marrow Transplantation·R TamariR Hoffman
Nov 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Haefaa AlchalbyUNKNOWN Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Sep 25, 2012·Leukemia Research·Ruben A Mesa, Raoul Tibes
Dec 5, 2014·Blood·Holly L Geyer, Ruben A Mesa
Feb 20, 2015·Hematology·Holly L Geyer, Ruben A Mesa
Dec 23, 2014·Future Oncology·Vijaya Raj Bhatt
Sep 25, 2016·Current Hematologic Malignancy Reports·Chetasi Talati, Eric Padron
Oct 26, 2018·Current Hematologic Malignancy Reports·Bing LiRaajit K Rampal
Dec 25, 2013·Current Opinion in Hematology·Raajit Rampal, John Mascarenhas
May 21, 2020·Blood·Andrew J DunbarRoss Levine
Jul 8, 2016·Expert Review of Hematology·Kristen Pettit, Olatoyosi Odenike
Mar 2, 2021·Hematology/oncology Clinics of North America·Tania Jain, Raajit K Rampal
Mar 3, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mathilde RuggiuGérard Socié

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.